Fred E. Cohen - 12 Jun 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Jun 2024, 16:19:29 UTC
Prior SEC filing
28 May 2024
Next SEC filing
20 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
James Basta, attorney-in-fact

Key filing fact

Fred E. Cohen filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 14 Jun 2024.

Key facts

  • This page summarizes Fred E. Cohen's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 14 Jun 2024, 16:19.

Change

  • Previous filing in this sequence was filed on 28 May 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Award

Transaction value
$0
Shares
+7,737
Change %
+19%
Price
$0.000000
Shares after
49,453
Date
12 Jun 2024
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NTLA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+11,515
Change %
Price
$0.000000
Shares after
11,515
Date
12 Jun 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,515
Exercise price
$25.85
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Footnote F2

This option was granted on June 12, 2024 with respect to 11,515 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .